Dr Reddy’s Q2 profit falls 36%, plans semaglutide relaunch in November

Mint - Oct 23, 2026

Lower US sales of generic Revlimid dragged down second-quarter earnings, but double-digit growth in base markets and the upcoming relaunch of semaglutide offer near-term relief.

Read full article

More News

The Daily Feeder

A leading news network dedicated to keeping you up-to-date on the world's most important political, business, and cultural news into a three-minute read.

NEWSLETTER